Skip to content
The Policy VaultThe Policy Vault

Votrient (pazopanib tablets)Cigna

Thyroid Carcinoma, Differentiated

Initial criteria

  • Patient age ≥ 18 years
  • Patient has papillary OR follicular thyroid carcinoma refractory to radioactive iodine therapy OR patient has oncocytic carcinoma (formerly Hürthle cell carcinoma)

Approval duration

1 year